ObsEva SA to Participate in Upcoming Investor Conferences
May 16, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – May 16, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva Reports First Quarter 2019 Financial Results
May 09, 2019 01:15 ET
|
ObsEva SA
2019 Phase 3 Data Readouts on track for nolasiban in IVF and linzagolix in uterine fibroids; MAA submission for nolasiban IVF therapy targeted by year-end ...
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
May 09, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019
May 08, 2019 16:30 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – May 8, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain
May 03, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and...
ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019
May 01, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA –May 1, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
April 29, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders
March 29, 2019 02:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – March 29, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
March 13, 2019 02:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston – March 13, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update
March 05, 2019 01:00 ET
|
ObsEva SA
Major 2018 Accomplishments Driven by Positive Clinical Trial Results -Significant increase in rates of pregnancy and live birth (up to 35% increase in Day 5 ET) in Phase 3...